Policy & Regulation
ImmunityBio reports promising survival and immune recovery in recurrent glioblastoma study
23 January 2026 - Commercial-stage immunotherapy company ImmunityBio Inc (NASDAQ:IBRX) on Friday announced updated Phase 2 results from QUILT-3.078, evaluating a chemotherapy-free combination of ANKTI...
Sanofi advances amlitelimab toward global filings after phase 3 results in atopic dermatitis
23 January 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) on Friday reported positive data from two global phase 3 studies, SHORE and COAST 2, supporting the potential ...
Trevi Therapeutics reports key Phase 2b CORAL trial results for oral nalbuphine ER
23 January 2026 - Clinical-stage biopharmaceutical company Trevi Therapeutics Inc (Nasdaq:TRVI) announced on Thursday that key results from the Phase 2b CORAL trial of oral nalbuphine ER for the treat...
Hansa Biopharma receives 2025 SwedenBIO Award
23 January 2026 - Swedish biopharmaceutical company Hansa Biopharma AB (STO:HNSA) announced on Thursday that it has received the 2025 SwedenBIO Award at the SwedenBIO Summit in Stockholm.This award ai...
Mabwell reports first patient dosed with 7MW4911 in US trial
23 January 2026 - Chinese biopharmaceutical company Mabwell (SHA:688062) announced on Thursday that the first patient has been dosed in a US clinical trial of its independently developed novel CDH17-t...
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
22 January 2026 - Clinical-stage biopharmaceutical company Atossa Therapeutics Inc (Nasdaq: ATOS) announced on Wednesday that The Healthcare Technology Report has recognized the company's founder...